Latest Conference Articles

Non-steroidal mineralocorticoid receptor antagonist, finerenone, demonstrated improved efficacy compared with existing steroidal treatment for patients.

Significant commonalities between type 2 diabetes and neurodegenerative disorders suggest that treatments effective for one condition may benefit the other.

Improvements were observed in both the intervention and control group, with those who had self-reported learning difficulties showing the least improvement.

Small adjustments in human pluripotent stem cell cultures and the molecule concentration patterns in the initial 5 days of differentiation are essential to “rescue” the lines.

In addition to a rapid deterioration, psychosis in Alzheimer disease can also lead to poorer quality of life, damaged patient-caregiver relationships, and increased isolation.

Edward B. Lee, MD, PhD, also describes how understanding Alzheimer disease requires the integration of multiple fields including genetics, pathology, epidemiology, pharmacology, and physiology.

Study results demonstrated that lecanemab provided sustained benefits over 36 months, such as improved biomarker profiles and slowed cognitive decline compared with placebo.

Tara Spires-Jones, DPhil, FMedSci, discusses how oligomeric tau clumps inside brain synapses, pointing to indirect evidence that it may be progressing through the brain by jumping between connections.

The co-founder, chief science officer, and chairman at Longeveron discusses the findings from the phase 2a trial CLEARMIND, as well as next steps to developing the therapy Lomecel-B.

Understanding and accounting for linguistic diversity is critical in diagnostics and treatment for dementia.

Joshua Hare describes how Lomecel-B addresses neuroinflammation, unlike other treatments which typically target amyloid disposition.

An extension of a long-acting cabotegravir study shows safety prior to and during pregnancy in cisgender women, with full results being presented at the 2024 International AIDS Conference.

Adherence and efficacy were both higher in patients with HIV who took twice-yearly lenacapavir compared to those on oral preexposure prophylaxis medication.

In the session at the 2024 American Association of Colleges of Pharmacy Annual Meeting, presenters highlighted the importance of fostering inclusion for LGBTQ students.

Educators should prioritize integrating social determinants of health (SDOH) for the next generation of pharmacists.

Students express interest in whole-person care and identify it as a gap in their education.

Both economic factors and supply chain fragility play a role.

Safety and efficacy findings on Lomecel-B will be presented at the upcoming 2024 Alzheimer’s Association International Conference, which will be held July 28 to August 1.

The Pharmacy Quality Alliance Annual Meeting highlighted social determinants of health, oral oncolytics, and screening opportunities.

NADINA trial results support a new standard of care for these patients.

Data presented show significant advancements in treatment options.

The 2024 American Society. ofClinical Oncology (ASCO) Annual Meeting in Chicago, Illinois, highlighted significant advancements across various oncology disciplines.

Panelists identify key public policies that pharmacies would benefit from acting on in 2024.

McKesson and state associations are advocating for community pharmacies through initiatives like McKesson Amplify that support advocacy work.

Pharmacists can play a crucial role in diabetes management by implementing standing order protocols for medication titration and serving as a bridge between patients and other health care providers.

Many patients who took technosphere insulin saw improvements in hemoglobin A1c, but other patients saw worsening with the drug.

The CATALYST trial has identified hypercortisolism as a significant factor in approximately 1.2 to 1.3 million poorly controlled diabetes patients in the United States.

Omar Nadeem, MD, discusses positive outcomes associated with GPRC5D-targeted CAR T-cell therapy.

Follow-up data reveal 10-year impact of ibrutinib in treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL).